Everhart Financial Group Inc. Buys 1,795 Shares of Amgen Inc. (NASDAQ:AMGN)

Everhart Financial Group Inc. boosted its holdings in Amgen Inc. (NASDAQ:AMGN - Free Report) by 91.8% during the 1st quarter, according to the company in its most recent disclosure with the SEC. The fund owned 3,750 shares of the medical research company's stock after buying an additional 1,795 shares during the quarter. Everhart Financial Group Inc.'s holdings in Amgen were worth $1,168,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in AMGN. Tallon Kerry Patrick purchased a new position in Amgen during the 4th quarter worth approximately $270,000. Brighton Jones LLC grew its position in Amgen by 23.5% during the 4th quarter. Brighton Jones LLC now owns 27,468 shares of the medical research company's stock worth $7,159,000 after purchasing an additional 5,226 shares in the last quarter. Capital Advisors Inc. OK grew its position in Amgen by 13.1% during the 4th quarter. Capital Advisors Inc. OK now owns 2,404 shares of the medical research company's stock worth $627,000 after purchasing an additional 278 shares in the last quarter. Values First Advisors Inc. grew its position in Amgen by 90.7% during the 4th quarter. Values First Advisors Inc. now owns 593 shares of the medical research company's stock worth $154,000 after purchasing an additional 282 shares in the last quarter. Finally, Van ECK Associates Corp grew its position in Amgen by 263.8% during the 4th quarter. Van ECK Associates Corp now owns 1,038,593 shares of the medical research company's stock worth $270,699,000 after purchasing an additional 753,147 shares in the last quarter. 76.50% of the stock is currently owned by hedge funds and other institutional investors.

Insider Transactions at Amgen

In other news, SVP Rachna Khosla sold 1,500 shares of the business's stock in a transaction dated Thursday, June 5th. The shares were sold at an average price of $289.68, for a total transaction of $434,520.00. Following the transaction, the senior vice president now owns 8,162 shares in the company, valued at approximately $2,364,368.16. The trade was a 15.52% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Insiders own 0.76% of the company's stock.

Amgen Stock Performance

Amgen stock traded down $2.07 on Friday, reaching $295.22. 2,191,182 shares of the stock were exchanged, compared to its average volume of 2,820,660. The stock has a market cap of $158.74 billion, a PE ratio of 39.10, a PEG ratio of 2.63 and a beta of 0.51. The company has a current ratio of 1.26, a quick ratio of 0.95 and a debt-to-equity ratio of 9.62. Amgen Inc. has a twelve month low of $253.30 and a twelve month high of $346.85. The firm has a fifty day moving average price of $281.33 and a two-hundred day moving average price of $285.62.

Amgen (NASDAQ:AMGN - Get Free Report) last released its earnings results on Thursday, May 1st. The medical research company reported $4.90 earnings per share for the quarter, topping analysts' consensus estimates of $4.18 by $0.72. The firm had revenue of $8.15 billion during the quarter, compared to analyst estimates of $8.05 billion. Amgen had a net margin of 12.24% and a return on equity of 176.32%. The business's revenue was up 9.4% on a year-over-year basis. During the same quarter in the previous year, the business earned $3.96 EPS. Sell-side analysts anticipate that Amgen Inc. will post 20.62 EPS for the current year.

Analyst Ratings Changes

A number of equities research analysts have issued reports on AMGN shares. Morgan Stanley reissued an "equal weight" rating on shares of Amgen in a research note on Friday, May 2nd. Bank of America lifted their target price on shares of Amgen from $275.00 to $294.00 and gave the company an "underperform" rating in a research note on Wednesday, March 5th. Johnson Rice set a $294.00 target price on shares of Amgen in a research note on Wednesday, March 5th. Mizuho lifted their target price on shares of Amgen from $235.00 to $280.00 and gave the company a "neutral" rating in a research note on Wednesday, May 7th. Finally, Erste Group Bank lowered shares of Amgen from a "strong-buy" rating to a "hold" rating in a research note on Thursday, May 8th. Two research analysts have rated the stock with a sell rating, twelve have assigned a hold rating, nine have issued a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of "Hold" and an average target price of $309.22.

About Amgen

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.